Transcode Therapeutics

United States
Calumet City, Illinois, United States, 02458

Company profile

Transcode Therapeutics company profile

TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, which they believe has blockbuster potential, targets an RNA molecule that is the driver of metastatic disease across multiple tumor types and has been validated pre-clinically in its lab at MGH.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2016-01-01

Headquarters

Postal code
02458
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
17
Total equity funding
$65M
Last funding
Post IPO Equity / $20M / 2025-10-08
Last equity funding
Post IPO Equity / $20M
Investors
5
Lead investors
3
Founders
2
Articles
150
Exited on
2021-07-09

Founders and investors

Founders

R. Michael DudleyZdravka Medarova

Lead investors

CK Life Sciences InternationalNational Cancer InstituteNational Institutes of Health

Investors

CK Life Sciences InternationalNational Cancer InstituteNational Institutes of HealthRed Cedar VenturesTRITON FUNDS LLC